뉴로핏

380550KOSDAQ소프트웨어 개발 및 공급업

50.9 / 100

Reference Date: 2026-07-24

Financial Score19.0 / 40

News Sentiment18.9 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 21.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neurophet is a company specializing in medical imaging solutions for neurodegenerative diseases, particularly Alzheimer's, offering products like Neurophet AQUA AD, which assesses Amyloid-Related Imaging Abnormalities (ARIA) severity. The company holds international certifications such as CE, FDA 510K, and GMP, and provides Clinical Research Organization (CRO) services to support medical device development.

Number of Employees

139people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.284.0Point

PBR

5.17Industry Average 0.890.0Point

5.8x industry avg (risky)

ROE

—Industry Average 1.103.5Point

Debt Ratio

2.55Industry Average 7.936.5Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

12 totalPositive 9Neutral 3Negative 0Average Sentiment Score 75.4

Positive
뉴로핏, 알츠하이머 뇌 영상 분석 솔루션 ‘아쿠아 AD 플러스’ 산업....
뉴로핏의 알츠하이머 뇌 영상 분석 솔루션이 정부 혁신제품 지정으로 기술 경쟁력이 강화되어 긍정적인 시장 반응을 기대할 수 있다.
Positive
뉴로핏 아쿠아 AD 플러스, 산업부 혁신제품 지정
뉴로핏 아쿠아 AD 플러스의 혁신제품 지정으로 알츠하이머병 치료 분야에서의 기술적 우위와 시장 경쟁력 강화가 기대된다.
Neutral
빈준길 뉴로핏 대표 "경쟁사 경증 치중할 때 '뇌졸중' 선점…매출 더....

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 8,250Won52-week high 36,70052-week low 7,570

1-month return0.0Point

1m -21.43% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0